OBESITY OR OVERWEIGHT
Clinical trials for OBESITY OR OVERWEIGHT explained in plain language.
Never miss a new study
Get alerted when new OBESITY OR OVERWEIGHT trials appear
Sign up with your email to follow new studies for OBESITY OR OVERWEIGHT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New weight-loss drug tested in chinese adults with diabetes
Disease control CompletedThis early-stage study tested a new drug called AZD5004 in 45 Chinese adults who were overweight or obese, some with type 2 diabetes. The main goal was to check if the drug is safe and how the body processes it, compared to a placebo. Researchers measured side effects and drug le…
Matched conditions: OBESITY OR OVERWEIGHT
Phase: PHASE1 • Sponsor: Eccogene • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New weekly shot shows promise for weight loss in obesity trial
Disease control CompletedThis study tested a new medicine called AZD6234, given as a weekly shot, to help people with obesity or overweight lose weight. 262 adults took part for 36 weeks. The main goal was to see if the drug helped people lose more weight than a placebo. The study is now complete, and re…
Matched conditions: OBESITY OR OVERWEIGHT
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New daily pill shows promise for weight loss in obesity study
Disease control CompletedThis study tested an experimental oral tablet called AZD5004 to see if it helps people with obesity or overweight lose weight. About 310 adults took the pill or a placebo once daily for 36 weeks. The goal was to measure weight loss and safety. This is a phase 2 trial, meaning it'…
Matched conditions: OBESITY OR OVERWEIGHT
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo shot CagriSema shows major weight loss in chinese trial
Disease control CompletedThis study tested a new weekly injection called CagriSema (a mix of two medicines) in 300 Chinese adults with obesity or overweight. Participants received either CagriSema, a dummy shot, or semaglutide alone for about a year. The main goal was to see how much weight they lost and…
Matched conditions: OBESITY OR OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New combo shot helps east asians shed pounds in major trial
Disease control CompletedThis study tested a new weekly injection called CagriSema (a mix of two medicines) in 331 East Asian adults with obesity or overweight. The goal was to see how much weight people lost compared to taking semaglutide alone. The trial lasted about 1.5 years, and participants receive…
Matched conditions: OBESITY OR OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 22, 2026 13:50 UTC